[Clinical and pathological efficacies of intra-arterial infusion chemotherapy and radiotherapy combined with hormone therapy in prostate cancer].
Eleven patients with prostate cancer were treated by intra-arterial infusion chemotherapy and radiotherapy combined with hormone therapy. CDDP was given one patient, THP and CDDP to eight patients, and THP and CBDCA to two others. All patients were treated by whole pelvis with prostate boost radiation. Seven patients underwent castration and four were administered LH-RH agonist in hormone therapy. Clinically, CR was observed in two patients and PR in nine. Histologically, G3 was observed in six patients, G2 in four patients and G1 in one. The main side effects were myelosuppression and rectal disturbances, but treatment could be completed in all patients. These results suggest that this treatment is a useful regimen for prostate cancer.
Inoue
Y
Y
Dept. of Urology, Shikoku Cancer Center.
Akiyama
M
M
Hashine
K
K
Sumiyoshi
Y
Y
D000368:Aged; D000369:Aged, 80 and over; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D016190:Carboplatin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D004334:Drug Administration Schedule; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors; D006801:Humans; D007261:Infusions, Intra-Arterial; D008297:Male; D008875:Middle Aged; D009919:Orchiectomy; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D011879:Radiotherapy Dosage
D000903:Antibiotics, Antineoplastic; D007987:Gonadotropin-Releasing Hormone; D004317:Doxorubicin; D016190:Carboplatin; C027260:pirarubicin; D002945:Cisplatin